David Gross

David Gross is Managing Partner at Bain Capital, one of the world’s top private investment firms.

Mr. Gross graduated from the University of Pennsylvania’s Wharton School with a BS in Economics. He also earned an MBA from Harvard Business School as a Baker scholar. Early in his career, Mr. Gross was hired to work in Tokyo for NEC as part of that company’s push to recruit young professionals. In 1998, he started a consulting job with Bain & Company and later joined Bain Capital in 2000.

He participated in establishing the firm’s Asia presence, which has grown from one to ten offices across the region. He played a role in helping expand Bain Capital regional enterprises in life sciences, private credit, private equity (including Asia-focused buyout funds), special situations and technology. Mr. Gross also helped pioneer Bain Capital’s Macro team, which analyzes big-picture economic factors—such as trade issues and geopolitical relationships—to assist in guiding the firm’s investment strategies.

Various financial programs have featured Mr. Gross. At the 2025 Milken Institute Global Conference event, Mr. Gross was a panelist for “The New Age of Private Equity,” where he discussed how the capital investment landscape has changed. Mr. Gross was also featured on CNBC Asia about Bain Capital’s investing strategies in the region, and on Bloomberg’s “Open Interest” about navigating macroeconomic conditions to encourage positive outcomes.

He was a guest on Private Equity International’s “Spotlight” podcast for a discussion on market uncertainty and the “Goldman Sachs Exchanges: Great Investors” podcast, where he shared insights on the evolution of private equity.

Outside his Bain Capital career, Mr. Gross is a member of the Board of Overseers for the School of Arts and Sciences at the University of Pennsylvania, where he also advises the Center for the Advanced Study of India and the Kelly Writers House. Mr. Gross is on the Board of Trustees for the Berklee College of Music, and the boards of the Dana-Farber Cancer Institute and the Boston Children’s Hospital Trust.